MedPath

Examination of post-ERCP pancreatitis preventive effect of load infusion therapy with lactated Ringer's solution Randomized controlled trial

Recruiting
Conditions
Biliary-pancreatic diseases for which ERCP is indicated
Registration Number
jRCTs031200202
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
950
Inclusion Criteria

(1) Patients aged 20 to 85 at the time of consent acquisition (2) Gender: Any (3) Patients who are clinically indicated for ERCP and undergo ERCP (malignant biliary stricture, pancreatic cancer, acute cholangitis, common bile duct stone, IgG4 sclerosing cholangitis, primary sclerosing cholangitis, etc.) (4) Post-ERCP pancreatitis risk (moderate or higher) (5) PS is 2 or less (6) Patients who can take oral drugs, meals and beverages (7) Patients expected to have stable primary disease (including cancer) 6 months after registration during the observation period (8) Patients who have written informed consent to participate in this study, who comply with the compliance items during this study participation, who can receive the medical examination prescribed in this study plan and report symptoms etc.

Exclusion Criteria

(1) Patients with low risk of post-ERCP pancreatitis (confirmed cases of chronic pancreatitis, pancreatic head tumor, periodic biliary stent replacement) (2) Patients with acute pancreatitis (3) Patients with hypotension including sepsis (4) Heart failure patients (NYHA Class II or above) (5) Patients with renal failure (creatinine clearance <30 mL/min) (6) Patients with liver failure (patients with cirrhosis and ascites) (7) Patients with respiratory failure (defined as oxygen saturation <90%) (8) Hyponatremia (Na+ levels <130mEq/L) (9) Hypernatremia (Na+ levels> 150mEq/L) (10) Hypokalemia (K+ levels <3.0mEq/L) (11) Patients who are pregnant or breastfeeding, patients who wish to become pregnant during the study period, patients who wish to become pregnant of a partner during the study period. (12) In addition, patients who are judged to be unsuitable for study participation by the investigator or investigator based on combination therapy and medical findings. (13) Patients in other clinical studies or clinical trials

Study & Design

Study Type
Interventional
Study Design
parallel assignment
Primary Outcome Measures
NameTimeMethod
Post-ERCP pancreatitis incidencewithin 24 hours after ERCP

This study examines the post-ERCP pancreatitis preventive effect of fluid loading. Therefore, the primary evaluation item this time is the post-ERCP pancreatitis incidence rate as a direct evaluation item.

**Diagnostic criteria for post-ERCP pancreatitis**

(1) Newly developed upper abdominal pain

(2) Pancreatic enzymes (amylase and/or lipase) increased more than 3 times the institutional upper limit of normal

(3) (1) and (2) within 24 hours after ERCP

(4) Hospitalization extension of 2 nights or more

Post-ERCP pancreatitis if all of the above are met

Secondary Outcome Measures
NameTimeMethod
Severity evaluation by Cotton classification

Severity endpoint

- Mild: Clinical symptoms of acute pancreatitis, and amylase at least 3 times normal after 24 hours of procedure, requiring emergency hospitalization, or extended hospitalization for 2-3 days

- Moderate: Hospitalization for 4-10 days

- Severe cases requiring: 10 days or more hospitalization, necrosis or pseudocyst formation, or percutaneous drainage or surgery required

Severity evaluation based on pancreatitis clinical practice guidelines

Severe pancreatitis Judgment items:

- Prognostic factors (described below) 3 points or more

- or contrast CT Grade 2 points or more

Post-ERCP pancreatitis CT Grade

Evaluation of pancreatitis severity by CT:

- CT Grade classification by contrast-enhanced CT

- Evaluate the extent of inflammation outside the pancreas and the area of poor contrast of the pancreas as follows

Severity assessment by Atlanta classificationat least 30 days after ERCP

For the following, follow-up including late complications will be performed for at least 30 days after ERCP.

- Presence or absence of other complications (pancreatitis after late ERCP, bleeding, renal disorder, heart failure, etc.)

- Length of hospitalization

- Examination of relevance to other factors (With or without NSAIDs, with or without pancreatic stent placement, with or without history of pancreatitis, with or without ERCP, with or without EST, with or without precut, with or without pancreatography, papillary dysfunction, with nipple resection, with trainees, gender, age, between institutions, etc.)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.